• Explore /
  • Poster
  • / Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas.

Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas.

Abstract Video & Slides Poster

Authors

null

Ryan C Lynch

University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA

Ryan C Lynch , Christina Poh , Chaitra Shankar Ujjani , Edus H. Warren III, Stephen Douglas Smith , Mazyar Shadman , Karolyn Morris , Heather Rasmussen , Susan Ottemiller , Megan Shelby , Sarith Keo , Jake J. Chabon , Ted Gooley , Jenna M. Voutsinas , Ajay K. Gopal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04231877

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7546)

DOI

10.1200/JCO.2022.40.16_suppl.7546

Abstract #

7546

Poster Bd #

199

Abstract Disclosures

Similar Posters

First Author: Bei Hu

First Author: Lorenzo Falchi

First Author: Herve Tilly

First Author: Jason Westin